Mimicking the tumour microenvironment (TME): Angiogenesis
in tumour progression.
Not exact matches
«Naked mole rats have an additional barrier
in the way of
tumour progression,» says Seluanov, who presented the results at the Strategies for Engineered Negligible Senescence meeting
in Cambridge, UK, last week.
Although these results are an important step forward
in understanding the mechanisms of
tumour progression, more research is needed before this treatment can be applied to clinical practice.
The addition of necitumumab to gemcitabine and cisplatin chemotherapy improved overall survival and
progression free survival by 21 % and 16 %, respectively, as compared to chemotherapy alone
in patients whose
tumours expressed the EGFR protein.
«The new knowledge we have gained facilitates the design of prophylactic and therapeutic measures for delaying
tumour progression and extending cancer - free periods
in RDEB,» says Venugopal Rao Mittapalli, the first author of the study.
For patients with cervical cancer that has recurred after treatment or has spread elsewhere
in the body, adding the experimental drug cediranib to standard chemotherapy improves
tumour shrinkage and adds a modest improvement
in progression - free survival, researchers report at the ESMO 2014 Congress
in Madrid.
«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid
tumours have resulted
in median gains
in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»
Most of the studies have focused mainly on
tumour cells, whilst the cells that form the stroma are the great unknown,
in spite of different research groups proving that some components of stroma promote the
tumour progression.
However, a
tumour can trick neutrophils to become activated even
in the absence of an infection, and as a consequence they contribute to disease
progression and tissue damage.
By conducting an RNA - sequencing experiment of 103 matched
tumour and normal colon mucosa samples from Danish CRC patients, 90 of which were germline - genotyped, researchers from the collaborative European project SYSCOL show that both inherited and acquired mutations
in non-coding regions of the genome also contribute to cancer development and
progression (Linda Koch, Nature Reviews Genetics).
We then monitored mammary
tumour incidence and
progression in this mouse line on Slc6a14 + / + and Slc6a14 − / − genetic backgrounds.
Senescent cells may promote
tumour progression through the activation of a senescence - associated secretory phenotype (SASP), whether these cells are capable of initiating tumourigenesis
in vivo is not known.
Because the
tumour is located
in an area of the brain which makes surgery risky, Alix is on a watchful waiting program, with brain scans every six months to monitor for
progression.